Aridis Pharmaceuticals, Inc.

Dr. Simrit Parmar at Texas A&M University has developed an innovative umbilical cord blood-derived T regulatory cell therapy that has demonstrated safety and efficacy in treating over 80 patients with ALS and other inflammatory diseases.

Vasomune Therapeutics will present late-breaking research showing how their lead candidate AV-001 protects against endothelial cell permeability induced by SARS-CoV-2 infection at the 2025 American Thoracic Society Conference.

Faron Pharmaceuticals' lead product Traumakine, an intravenous interferon beta treatment for Acute Respiratory Distress Syndrome, has been granted PIM designation by UK authorities.

• Alexion Pharmaceuticals is initiating a Phase 3 clinical trial of Ultomiris (ravulizumab) in 270 patients with severe COVID-19 pneumonia or acute respiratory distress syndrome. • The study will evaluate Ultomiris's impact on patient survival, ventilation duration, and hospital stay length, targeting the complement system's role in severe COVID-19 complications. • The decision follows promising compassionate use results with Soliris and leverages Ultomiris's longer-lasting formulation and weight-based dosing schedule for optimal hospital administration.

• InflaRx's Gohibic is the first and only treatment approved in the EU for SARS-CoV-2-induced ARDS, marking a significant milestone. • The European Commission's approval was based on positive Phase 3 PANAMO trial results, demonstrating a 23.9% reduction in mortality. • H.C. Wainwright reiterated a Buy rating for InflaRx, setting a price target of $8.00, citing Gohibic's market potential and pipeline. • InflaRx is exploring partnership and distribution options in Europe and is in discussions with the FDA for potential US approval.

InflaRx's Gohibic (vilobelimab) has been granted marketing authorization in the EU for treating SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).

Talphera has reached an agreement with the FDA for a Prior Approval Supplement (PAS) review to reduce the number of patients in the NEPHRO CRRT study.

A randomized controlled trial evaluated two dexamethasone dosing regimens in COVID-19 patients with moderate to severe ARDS.

Narsoplimab significantly reduced the risk of mortality in high-risk TA-TMA patients by over 3-fold compared to an external control group.

Edesa Biotech strategically shifted its anti-TLR4 drug candidate (EB05) towards a U.S. government-funded study for Acute Respiratory Distress Syndrome (ARDS) treatment.